Navigation Links
NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
Date:3/19/2008

ample of this strategy. In addition, through partnerships with generic pharmaceutical businesses, Archimica is building its product portfolio for the generic pharmaceutical industry.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of NCEs in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") s
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. NicOx Opens U.S. Headquarters in New Jersey
2. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
3. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. Monsanto Company Signs Share Subscription Agreement With Devgen
8. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
9. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
10. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
11. Assay Designs(TM) Announces Additions to the Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Technological University (NTU) signed the Memorandum of Understanding ... Research (CNRS) and the Thales Group of Companies ... three parties are meeting again in Singapore to ... NTU. , Located at the Research Techno ... latest in science and technology to develop innovations ...
(Date:12/16/2009)... Nursing Care at Hahnemann among the Best in ... -- Hahnemann University Hospital proudly announces it has ... Credentialing Center,s (ANCC) Magnet Recognition Program(R). Magnet(R) is ... hospital or medical center can achieve, and places ... the country that have achieved this prestigious distinction. ...
(Date:12/16/2009)... Dec. 16 /PRNewswire/ -- ... life sciences industry and an active venture capital ... Indiana State Teachers Retirement Fund, Indiana University, Purdue ... Fairbanks Foundation, and Credit Suisse today announced the ... venture capital fund of funds. ,, Organized through ...
(Date:12/16/2009)... -- Sequenom, Inc. (Nasdaq: SQNM ), today ... Mr. David Pendarvis to its board of directors. ... Kenneth F. Buechler, Ph.D., was president, chief scientific ... to 1994, Dr. Buechler was Biosite,s director of ... a senior research scientist for the diagnostics research ...
Breaking Biology Technology:New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3
... the successful acquisition of,Drug Development Solutions (,DDS,) in ... that it has fully,integrated its two early Phase ... Phase., Chiltern Early Phase is providing high ... its two well established units in Slough,(just outside ...
... BANKING FIRM HAS STRONG BACKGROUND IN BIOTECHNOLOGY, ... "the Company") (OTC Bulletin Board: SOBM) is pleased ... Inc. as its financial,advisor to evaluate strategic alternatives ... extremely pleased with the results obtained from the ...
... Amylin,Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli ... call today provided context and additional information,regarding the August ... a prior alert for BYETTA(R) (exenatide) injection referencing,pancreatitis. The ... alert, as well as others, and previously reported these ...
Other Biology Technology:Chiltern Early Phase: Fully Integrated and Business Ready 2Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value 2Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6
(Date:12/17/2009)... Department of Energy,s Savannah River National Laboratory (SRNL) ... SRNL,s unique Porous Walled Hollow Glass Microspheres available ... and other uses, including applications still being developed. ... years in light-weight filler material, insulation, abrasives and ... unique is the network of interconnected pores in ...
(Date:12/17/2009)... Mass., December 17, 2009 Maternal behavior itself ... the maternal brain independent of whether the female ... study released by researchers at Tufts University,s Cummings ... adult, virgin rats were published in Brain ... http://dx.doi.org/10.1016/j.brainresbull.2009.08.011 . , In the study, ...
(Date:12/17/2009)... another mass extinction like the previous five, each of which ... the planet, then North American mammals are one-fifth to one-half ... and Pennsylvania State University analysis. , Many scientists warn that ... both the result of human activity is leading ... that have occurred over the past 450 million years, the ...
Breaking Biology News(10 mins):MO-SCI Corporation to manufacture, market SRNL's unique glass microspheres 2Exposure to young triggers new neuron creation in females exhibiting maternal behavior 2Study shows loss of 15-42 percent of mammals in North America 2Study shows loss of 15-42 percent of mammals in North America 3Labor Board Decision Puts Kaiser Workers Pay Healthcare Pensions in Jeopardy 62391 1Labor Board Decision Puts Kaiser Workers Pay Healthcare Pensions in Jeopardy 62391 2Patient Safety Technologies Inc Appoints Marc L Rose CPA 28PA 29 Chief Financial Officer 6662 1Patient Safety Technologies Inc Appoints Marc L Rose CPA 28PA 29 Chief Financial Officer 6662 2New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 1New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 2New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 3New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 4New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 5New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 6New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6657 7
... renowned marine ecologist with Scripps Institution of Oceanography at ... 11th annual Roger Tory Peterson Medal presented by the ... Roger Tory Peterson Memorial Lecture on Sunday, April 6, ... Center. , In his lecture, entitled Brave ...
... HARBOR, N.Y. In a provocative new book, distinguished ... scientific view of human nature, one that is based on ... , , [M]ost of humanity has an outmoded and inadequate perception ... the first or second millennium, writes Carlson in the Preface ...
... may be more effective than the standard 28-day birth ... They say that the continuous pill also causes a ... provided a biological proof of concept that both the ... better and quicker with the continuous pill than with ...
Other Biology News:Jeremy Jackson honored by Harvard Museum of Natural History 2A call to infuse scientific knowledge into the human experience 2Continuous oral contraceptives better at easing pain, bleeding 2Continuous oral contraceptives better at easing pain, bleeding 3
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
... been developed specifically for the stabilization ... microwell plates/strips. Coating Stabilizer maintains ... antibody or protein antigen portion of ... is filtered at 0.2 microns., ,Contents: ...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: